Monday, December 5, 2022
HomeAltcoinsTop crypto exchange BitMart lists the Aimedis token on its platform

Top crypto exchange BitMart lists the Aimedis token on its platform

On August 29, Michael J. Kaldasch, founder and CEO of Aimedis, announced in a press release that the Aimedis token (AIMX) will now be available to trade on the cryptocurrency trading platform, BitMart, from August 29, 2022.

Michael J. Kaldasch said, “We are glad to announce that the Aimedis token AIMX will be traded on BitMart.”

BitMart is a user-friendly crypto trading platform and it has more than 2.2 million international users who believe that decentralised currency is accessible to everybody, everywhere and also it provides real-time trading services, which also include well-known cryptocurrencies like ETH and BTC.

CEO of Aimedis continued and said, ‘as we are continuously growing by collaborating with new partners and clients, this seems to be the next logical step for our organization.”

The most recent clients of Aimedis Avalon consist of well-known university hospitals. Apart from the university hospitals some major pharma companies and global-level medical service organisation networks like HAVAS healthcare & You/HAVAS NOW are also clients of Aimedis.

Ben El Idrissi, the COO and also the founder of Aimedis Avalon, said, “Aimedis is a secure metaverse platform. Apart from offering help, services and advice to doctors, healthcare professionals and patients it also makes education information accessible to students and patients all over the globe.”

In the closing remark Ben said, “we just participated with our CTO, Stefan Wiesner, as a board speaker in the APAC Patient Experience Innovation Summit at Bangkok and come across a lot of interested South-East Asia based healthcare hospital chains and companies, who are interested in going into metaverse with Aimedis Avalon.”

Additionally, Aimedis is planning to begin a second landsale in the next few weeks to move ahead and change the medical service industry.

Read more:

 

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

4 + five =

- Advertisment -

Most Popular